Which Anti-VEGF Therapy (Ranibizumab, Bevacizumab, or Aflibercept) Demonstrates The Most Cost-Effective Outcomes For Treating Age-Related Macular Degeneration ? : A Systematic Review. The Indonesian Journal of General Medicine, [S. l.], v. 12, n. 3, p. 1–48, 2025. DOI: 10.70070/vbsedq58. Disponível em: https://indonesianjournalmedicine.org/index.php/ijgm/article/view/142.. Acesso em: 21 oct. 2026.